Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous PBMC Modulated with IFNt for Endometrial Composition
NCT05775211Recruiting
- Sponsor
- Nadezhda Women's Health Hospital
- Start
- Mar 2023
- Primary completion
- Mar 2026
- Modality
- Cytokines & Interferons, Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of autologous peripheral blood mononuclear cells + interferon tau in Unexplained infertility, sponsored by Nadezhda Women's Health Hospital. Primary endpoint: Change in the numbers of certain endometrial cell populations. Started Mar 2023; status: recruiting.
02
Drugs
autologous peripheral blood mononuclear cells + interferon tau
03
Conditions
Unexplained infertility
Beyond the preview
Go deeper on NCT05775211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05775211.